Pulmologix, a Stockholm, Sweden-based developer of a new oral non-steroidal anti-asthmatic drug, raised €9.6M in Series B funding.
The round was led by Novo Seeds and Sunstone Capital with participation from previous investors Forbion Capital Partners and HealthCap. In conjunction with the funding, Bobby Soni, Investment Director of Novo Seeds and Andreas Segerros of Sunstone joined Pulmologix’ Board of Directors.
The company intends to use the funds to continue to develop a new Oral Non-‐Steroidal Anti-‐asthmatic (ONSA) for the treatment of early onset allergic asthma. Led by Dr Carl-‐Johan Dalsgaard, CEO and co-founder, Pulmologix is developing proprietary lead compound is targeting the allergic reaction triggering human asthma and is scheduled to enter phase I trials later this year and clinical proof of concept trials in 2015.